TO THE EDITOR
Splenic lymphoma with villous lymphocytes (SLVL) is usually an indolent mature B-cell lymphoproliferative disorder (B-CLD) recognized as a variant of marginal zone lymphoma. 1 The main characteristics are the presence of massive splenomegaly and absolute lymphocytosis with circulating villous lymphoid cells (VL). Splenectomy or chlorambucil (CLB) are regarded as the most effective treatment, particularly in patients with symptomatic splenomegaly, rapid increase of lymphocyte or severe pancytopenia. 2 However, splenectomy sometimes carries surgical risks; CLB is often not effective and relapse is frequent.
In this journal, we have previously reported the initial positive impact of fludarabine (FDR) in a substantial proportion of patients with SLVL. 3 We reported here with a longer follow-up, the long-term effect of FDR observed in our initial group of FDRtreated patients.
From 1994 to 1998, 10 consecutive SLVL patients, with a median age of 59 years (range, 37-74 years), were treated by FDR. No patients presented hepatitis C virus infection concomitant to SLVL, which may be cured by antiviral therapy. 4 Two patients received FDR as a first-line therapy and eight as a second-line therapy. Two were splenectomized with a transient response for a duration of 6 and 11 months, respectively. Six patients received before other chemotherapies (CLB, cyclophosphamide or CHOP regimen with transient success in only two cases). The median time from diagnosis to FDR therapy was 17 months (range, 1-30 months). Eight patients received 4 monthly courses at a daily dose of 25 mg/ m 2 /day for 5 days. Two patients received two and six courses, respectively. A good response (GR) was defined as the disappearance of splenomegaly, a platelet count superior to 100 Â 10 9 /l, absolute neutrophil count (ANC) 41 Â 10 9 /l, hemoglobin level superior to 10 g/dl and the absence of blood circulating VL. A partial response (PR) was defined by at least a 50% reduction in splenomegaly, with a persisting organomegaly and by improvement in hematological parameters over baseline, but ANC inferior to 1 Â 10 9 /l, platelet count inferior to 100 Â 10 9 /l or hemoglobin level inferior to 10 g/dl. Failure was defined as a persistent or progressive increase in the number of peripheral blood VL and/or splenomegaly. Relapse was defined as a progressive increase in the number of peripheral blood VL and/or increasing splenomegaly after an initial GR or PR.
Seven patients achieved a GR. Four of them relapsed between 15 and 60 months following FRD therapy. Three patients achieved a PR and relapsed 10, 18 and 20 months later, respectively. No failure was observed. Eight of 10 patients remain alive at the time of data analysis (January, 2004). One patient died from infectious complications after relapse and a new therapy by 2-chloro-deoxyadenosine and the second deceased from unrelated disease. The median overall survival (OS) is still not achieved after a median follow-up of 6 years and 8 months from the time of FDR therapy. In addition, three (30%) patients remain alive and progression free 6-7 years after treatment avoiding splenectomy (all these patients relapsed or were refractory after initial therapy by CLB). These data result in a median event-free survival (EFS) of 4.7 years (95% confidence interval, 1.56-not reached).
SLVL has a relatively clinical benign course. However, a few patients could require treatment, because of a symptomatic splenomegaly, an increase in the number of blood VL or a severe cytopenia. A relapse or a failure after splenectomy and/ or chemotherapy could be a difficult challenge. In a previous series of 50 patients, Mulligan et al 5 reported a 3-year OS of 82%. Splenectomy was performed in 20 patients and a GR was sustained in 17 patients for a median of 4 years. The response to chemotherapy was poor: in 18 patients treated in first line, only eight were good responders and 10 patients had minor or no response. In a previous study conducted from 100 patients with SLVL, we have reported a 5-year OS rate of 78%. 2 Only 15 patients died from progressive disease or related treatment complications; 21/28 (75%) splenectomized patients had good PR, but 7/23 (30%) relapsed. 2 The results after chemotherapy were similar to Mulligan's in which 10 out of 19 patients are good partial responders and nine exhibit minimal or no response. 5 All our patients were responders to FDR with seven and three good and partial prolonged responses obtained, respectively. The median OS from diagnosis is still not achieved after a median follow-up of 6 years plus 8 months and the median EFS of 4.7 years constitutes encouraging results. In addition, the few patients remaining alive and progression free 6-7 years after FDR therapy may expect a possible cure without splenectomy in some cases. Unfortunately, no clear prognostic factors could be identified for FDR response in our group of patients. The experience of purine analogues as FDR in the treatment of SLVL is limited. Bolam reported four cases of resistant or relapsing SLVL successfully treated by FDR with a lasting GR for two of them, the other two died from unrelated diseases. 6 Yasukawa reported a case of SLVL in which the splenomegaly increased rapidly despite splenic irradiation and combination chemotherapy, while a complete remission lasting for more than 15 months was achieved with a low dose of FDR. 7 In conclusion, our results confirm that FDR could be an effective therapy for patients in relapse after splenectomy and/or resistant to CLB, allowing long-term sustained complete hematological remission in some patients. Furthermore, FDR could constitute an alternative to splenectomy for older patients and prospective studies might be warranted to assess its efficiency as first-line therapy. 
